AbbVie Inc. (ABBV) Property, Plant & Equipment
The pp&e for AbbVie Inc. (ABBV) is $6.37 Billion with a year-over-year change of +23.98%. Property, Plant & Equipment (PP&E) represents the long-term tangible assets used in operations, including land, buildings, machinery, and equipment, shown net of accumulated depreciation.
ABBV PP&E Chart
Current PP&E
$6.37B
$6.37 Billion
Year-over-Year Change
+23.98%
vs. $5.13B prior year
Historical Data
16
Years of data available
Annual PP&E History
| Year | PP&E | YoY Change | % Change |
|---|---|---|---|
| 2025 | $6.37B | +$1.23B | +23.98% |
| 2024 | $5.13B | +$145.00M | +2.91% |
| 2023 | $4.99B | +$54.00M | +1.09% |
| 2022 | $4.93B | $-175.00M | -3.42% |
| 2021 | $5.11B | $-138.00M | -2.63% |
| 2020 | $5.25B | +$2.29B | +77.18% |
| 2019 | $2.96B | +$79.00M | +2.74% |
| 2018 | $2.88B | +$80.00M | +2.85% |
| 2017 | $2.80B | +$199.00M | +7.64% |
| 2016 | $2.60B | +$39.00M | +1.52% |
| 2015 | $2.56B | +$80.00M | +3.22% |
| 2014 | $2.48B | +$187.00M | +8.14% |
| 2013 | $2.30B | +$51.00M | +2.27% |
| 2012 | $2.25B | +$103.00M | +4.80% |
| 2011 | $2.14B | $-213.56M | -9.06% |
| 2010 | $2.36B | — | — |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael